This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Healthy Biotech and Pharma ETFs

Before the first ballot was cast in the 2008, Obama's quest for health care reform caused havoc in the sector and among health care ETFs like iShares Nasdaq Biotechnology (IBB) and HOLDRS Merrill Lynch Pharmaceutical ETF (PPH).

Government plans to extend health care to the uninsured and cut costs could certainly hinder major health care companies such as Amgen (AMGN) and Gilead (GILD), as lower costs cut into profits. Some analysts, however, believe that the influx of people into the heath care system and the bubble of aging baby boomers could make up for setbacks caused by reform.

ETFs provide access to a number of health care sectors, including biotech and pharmaceutical, giving investors a variety of approaches to diversify their portfolios. After surveying ETFs in both the biotech and pharmaceutical subsectors, IBB and PPH have emerged as two strong selections in a field of strong competitors.

The chance of any one biotech firm developing the next blockbuster drug are similar to the odds of moving to Hollywood and starring with Angelina Jolie in your first movie. That's not to say that biotech isn't a good place to have a small position -- biotech firms that make it do make it big and the reward for this sector is as high as the risk.

There is a broad range of biotech ETFs to choose from. The SPDR Biotech (XBI) and PowerShares Dynamic Biotech & Genome (PBE) funds offer investors balanced exposure to a broad range of biotech firms with an emphasis on small-cap companies. iShares Nasdaq Biotechnology (IBB) and Biotech HOLDrs (BBH) give investors exposure to the biggest names in the business.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
IBB $339.33 1.20%
PJP $74.12 1.20%
PPH $65.25 0.76%
PBE $51.73 1.49%
XBI $72.60 2.30%


Chart of I:DJI
DOW 17,836.44 +24.25 0.14%
S&P 500 2,091.46 +2.32 0.11%
NASDAQ 5,121.3420 +18.5340 0.36%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs